AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01579448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol™, killed, whole cell, bivalent, oral cholera vaccine
Description: This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension.
Study NCT01579448 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
Study NCT00542269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
Study NCT00542269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
Study NCT00542269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
Study NCT00542269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
Study NCT00542269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
Study NCT03611192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: Aerobic exercise: 15\~20 mins Resistance exercise: 15 mins Balance exercise: 15\~20 mins Flexibility exercise: 10 mins
Study NCT03611192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-program exercise
Description: 60 mins exercise
Study NCT01788254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study NCT01788254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study NCT01788254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study NCT01788254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talinolol
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study NCT01788254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torsemide
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study NCT03357679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Intubation of the trachea with endotracheal tube
Study NCT03357679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope assisted tracheal intubation
Description: With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube
Study NCT03357679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bed up head elevated tracheal intubation
Description: Use of the Macintosh laryngoscope blade size 3
Study NCT02404259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TDF (Tenofovir)
Study NCT02404259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz
Study NCT02404259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lopinavir/ritonavir, atazanavir/ritonavir
Study NCT01692275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care + Chiropractic Care
Description: Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
Study NCT01692275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Care Only
Description: Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
Study NCT02600832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AABM Training
Description: The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
Study NCT02600832 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Sham training is identical to AABM training, except pictures are presented randomly in both formats.
Study NCT01294579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years
Study NCT01294579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
Study NCT00531752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
Study NCT00531752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
Study NCT00531752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
Study NCT04261790 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ocrelizumab
Description: Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
Study NCT00401375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
Study NCT00401375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
Study NCT02849561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic hypothermia
Description: With a mattress at 4°C to reach a central temperature at 33,5°C.
Study NCT02849561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation
Description: Constant volume 6 ml/kg
Study NCT02849561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography
Study NCT02849561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pupillary light reflex surveillance
Description: With Neurolight® device.
Study NCT02849561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Doppler
Description: Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
Study NCT03268044 — intervention group
Intervention type: OTHER
Intervention: Hospital admission and surgery
Description: Hospital admission and noncardiac surgery
Study NCT04899700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linked Color Imaging
Description: Inspection of the postpolypectomy scar will be made with Linked Color Imaging
Study NCT04899700 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Linked Color Imaging
Description: Inspection of the postpolypectomy scar will be made with Linked Color Imaging
Study NCT04899700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White light endoscopy
Description: Inspection of the postpolypectomy scar will be made with White light Endoscopy
Study NCT04899700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White light endoscopy
Description: Inspection of the postpolypectomy scar will be made with White light Endoscopy
Study NCT00579852 — intervention group
Intervention type: PROCEDURE
Intervention: CT Scan
Description: Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
Study NCT01967537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Gallium DOTATATE
Description: Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
Study NCT01967537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-guided surgery
Description: Using 68Gallium DOTATATE
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg/m2 IV day 8 during cycles 1 to 8
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m2 po from day 1 to 7 during cycles 1 to 8
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2 po from day 1 to 14 during cycles 1 to 8
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 25 mg/m2 iv on days 1 and 15 in each cycle
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: 10 mg/m2 iv on days 1 and 15 in each cycle
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: 6 mg/m2 iv on days 1 and 15 in each cycle
Study NCT01251107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 375 mg/m2 iv on days 1 and 15 in each cycle
Study NCT03362424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
Study NCT03362424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Rotator cuff repair
Study NCT03362424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair
Description: Rotator cuff repair
Study NCT00350142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
Study NCT00350142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
Study NCT00350142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D pancreatic protocol CT scan
Description: Patients will undergo this imaging procedure prior to treatment for planning purposes.
Study NCT00350142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET scan
Description: Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
Study NCT05297942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expansion of Abbreviations and Acronyms
Description: Expansion of Abbreviations and Acronyms
Study NCT03371446 — intervention group
Intervention type: GENETIC
Intervention: oral epithelial cells obtained by rinsing with 3% sucrose
Description: rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
Study NCT03241953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery
Description: A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
Study NCT03241953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
Study NCT02827864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sequentially apply tDCS and MT
Description: The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
Study NCT02827864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: apply tDCS concurrently
Description: Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
Study NCT02827864 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: MT with sham tDCS
Description: The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
Study NCT03054376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: Full length cast of one leg R/L randomized
Study NCT03054376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with non immobilized leg
Description: Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
Study NCT03054376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training with both legs
Description: Exercise training will be conducted regularly on a cycle ergometer during a four week period
Study NCT03028571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
Study NCT03028571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
Study NCT01509196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP0901 / Lipidilsupra
Description: HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
Study NCT01509196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIP0901 / Lipidilsupra
Description: HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
Study NCT00947336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin + Synbiotic
Description: Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
Study NCT00947336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norfloxacin + Placebo
Description: Norfloxacin 400 mg once daily with placebo
Study NCT00562354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 13vPnC for both stratum
Study NCT03458208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition
Study NCT03458208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage®
Description: Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition
Study NCT02516241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion